Comment
doi: 10.1161/CIRCULATIONAHA.121.057835.
Epub 2022 Feb 7.
Why Are We Still Prescribing Angiotensin-Converting Enzyme Inhibitors?
Affiliations
- PMID: 35130055
- DOI: 10.1161/CIRCULATIONAHA.121.057835
Item in Clipboard
Comment
Why Are We Still Prescribing Angiotensin-Converting Enzyme Inhibitors?
Circulation.
.
No abstract available
Keywords: angiotensin receptor antagonists; angiotensin-converting enzyme inhibitors; myocardial infarction; randomized controlled trial.
Comment on
-
Comparative First-Line Effectiveness and Safety of ACE (Angiotensin-Converting Enzyme) Inhibitors and Angiotensin Receptor Blockers: A Multinational Cohort Study.Hypertension. 2021 Sep;78(3):591-603. doi: 10.1161/HYPERTENSIONAHA.120.16667. Epub 2021 Jul 26. Hypertension. 2021. PMID: 34304580 Free PMC article.
Similar articles
-
Clinical trials evaluating angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in the setting of acute myocardial infarction.Expert Opin Investig Drugs. 2003 Mar;12(3):501-7. doi: 10.1517/13543784.12.3.501. Expert Opin Investig Drugs. 2003. PMID: 12605571 Review.
-
The clinical use of angiotensin-converting enzyme inhibitors.Prog Cardiovasc Dis. 2004 Sep-Oct;47(2):116-30. doi: 10.1016/j.pcad.2004.04.003. Prog Cardiovasc Dis. 2004. PMID: 15586352 Review.
-
Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Myocardial Infarction.J Cardiovasc Pharmacol Ther. 2019 Jul;24(4):397. doi: 10.1177/1074248419841636. Epub 2019 Apr 29. J Cardiovasc Pharmacol Ther. 2019. PMID: 31035789 No abstract available.
-
Reply to Letter to the Editor-Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Myocardial Infarction.J Cardiovasc Pharmacol Ther. 2019 Jul;24(4):398. doi: 10.1177/1074248419845924. Epub 2019 May 1. J Cardiovasc Pharmacol Ther. 2019. PMID: 31043058 No abstract available.
-
Comparison between angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on the risk of myocardial infarction, stroke and death: a meta-analysis.J Hypertens. 2008 Jul;26(7):1282-9. doi: 10.1097/HJH.0b013e328306ebe2. J Hypertens. 2008. PMID: 18550998
Cited by
-
Impact of Antihypertensive Drug Class on Outcomes in SPRINT.Hypertension. 2022 May;79(5):1112-1121. doi: 10.1161/HYPERTENSIONAHA.121.18369. Epub 2022 Mar 9. Hypertension. 2022. PMID: 35259925 Free PMC article. Clinical Trial.
-
Comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on cardiovascular outcomes in older adults with type 2 diabetes mellitus: a target trial emulation study.Cardiovasc Diabetol. 2025 May 6;24(1):194. doi: 10.1186/s12933-025-02753-1. Cardiovasc Diabetol. 2025. PMID: 40329312 Free PMC article.
-
Decreased risk of radiation pneumonitis with concurrent use of renin-angiotensin system inhibitors in thoracic radiation therapy of lung cancer.Front Med (Lausanne). 2023 Oct 12;10:1255786. doi: 10.3389/fmed.2023.1255786. eCollection 2023. Front Med (Lausanne). 2023. PMID: 37901395 Free PMC article.
-
Impact of antihypertensive drug classes on cardiovascular outcomes: insights from the STEP study.BMC Med. 2025 Jul 1;23(1):365. doi: 10.1186/s12916-025-04158-z. BMC Med. 2025. PMID: 40598287 Free PMC article. Clinical Trial.
-
Chemical Synthesis, Safety and Efficacy of Antihypertensive Candidate Drug 221s (2,9).Molecules. 2023 Jun 25;28(13):4975. doi: 10.3390/molecules28134975. Molecules. 2023. PMID: 37446639 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
